Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | President, Global Hospital | July 26, 2024 | July 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date July 26, 2024 · Filed July 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,196 |
Reported balance
After 2024-07-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-07-26 · Sale · Disposed 4,312 · Balance 18,196 F1: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2: This number includes unvested restricted stock units previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).
F2: This number includes unvested restricted stock units previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2024 Filed Jul 29, 2024 21:03 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 4,312 | $91.15 | $393,038.80 |
DisclosureSEC source: 0001127602-24-021110 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,196 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 2,798 | $90.58 | $253,442.84 |
DisclosureSEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,508 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 20:34 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-021041 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,306 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on July 13, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from July 13, 2021 to July 12, 2024, as certified by the Compensation Committee of the Board of Directors on Jul 24, 2024. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 29, 2024 Filed May 29, 2024 21:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 8,857 | $87.53 | $775,253.21 |
DisclosureSEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,196 F4 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 4,399 | $95.73 | $421,116.27 |
DisclosureSEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,053 F3 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 28, 2024 Filed May 29, 2024 21:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 13,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016801 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,452 F1 · shares: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 20, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,241 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · derivative · entry 7 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,242 Underlying: Common Stock · 2,241 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F8 · derivative.exercise_date: Reflects options granted on May 18, 2021 that vest in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 20, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 686 | $95.11 | $65,245.46 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 5 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,196 F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 20, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,555 | $95.08 | $147,849.40 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 4 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,882 F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F6 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 20, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,241 | $56.57 | $126,773.37 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,313 | $0.00 Strike: $95.73 | $0.00 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · derivative · entry 6 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,313 Underlying: Common Stock · 6,313 shares Expires 2031-05-17 F7 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,196 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:01 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 284 | $95.73 | $27,187.32 |
DisclosureSEC source: 0001127602-24-016175 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,324 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,410 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · derivative · entry 6 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,821 Underlying: Common Stock · 2,410 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 733 | $96.04 | $70,397.32 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 5 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,608 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,677 | $96.14 | $161,226.78 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 4 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,341 F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F4 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,410 | $57.60 | $138,816.00 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 16, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 252 | $94.80 | $23,889.60 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,608 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 241 | $96.49 | $23,254.09 |
DisclosureSEC source: 0001127602-24-015888 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,860 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| October 20, 2023 Filed Oct 24, 2023 20:23 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 120 | $89.05 | $10,686.00 |
DisclosureSEC source: 0001127602-23-026191 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,101 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 20:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 228 | $90.65 | $20,668.20 |
DisclosureSEC source: 0001127602-23-024070 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,221 F1 · kind: Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023). F2 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 2,410 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · derivative · entry 6 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,231 Underlying: Common Stock · 2,410 shares Expires 2029-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,483 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · derivative · entry 5 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,483 Underlying: Common Stock · 4,483 shares Expires 2028-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 2,538 | $88.04 | $223,445.52 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 4 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,449 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.96 to $88.12, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this report. F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 5,053 | $88.00 | $444,664.00 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,987 F2 · shares: Represents shares withheld for tax obligations and for payment of the exercise price on exercised stock options reported in Table I. F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 2,410 | $57.60 | $138,816.00 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:16 UTC | HAEMONETICS CORP HAE · Entity 3953 | Exercise / conversionCommon Stock | 4,483 | $56.57 | $253,603.31 |
DisclosureSEC source: 0001127602-23-018423 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 1,087 | $83.34 | $90,590.58 |
DisclosureSEC source: 0001127602-23-016308 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,147 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2023 Filed May 17, 2023 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 250 | $89.21 | $22,302.50 |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,234 F4 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 6,335 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · derivative · entry 3 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,335 Underlying: Common Stock · 6,335 shares Expires 2030-05-15 F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:35 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015947 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,484 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 20:43 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 75 | $80.39 | $6,029.25 |
DisclosureSEC source: 0001127602-22-024416 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,681 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested restricted stock units ("RSUs") previously reported. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:18 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 1,084 | $59.10 | $64,064.40 |
DisclosureSEC source: 0001127602-22-015378 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,756 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 9,641 | $0.00 Strike: $57.60 | $0.00 |
DisclosureSEC source: 0001127602-22-014995 · form4.xml · derivative · entry 2 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,641 Underlying: Common Stock · 9,641 shares Expires 2029-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 21:13 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 4,123 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-014995 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,840 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 20:58 UTC | HAEMONETICS CORP HAE · Entity 3953 | SaleCommon Stock | 75 | $71.93 | $5,394.75 |
DisclosureSEC source: 0001127602-21-027704 · form4.xml · nonDerivative · entry 1 Strong Stewart W · CIK 0001420910 · President, Global Hospital 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,717 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.